Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell
transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of
MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD),
thereby improving the outcome of SCT.
Phase:
Phase 2
Details
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland